Literature DB >> 757962

Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxy tolbutamide in plasma.

R L Nation, G W Peng, W L Chiou.   

Abstract

A rapid high-pressure liquid chromatographic (HPLC) assay is described for the quantitative analysis of tolbutamide and its major metabolite, carboxy tolbutamide in plasma. An aliquot (25--100 microliter) of plasma was prepared for chromatography by deproteinization as follows. One volume of plasma and 2.5 volumes of acetonitrile were vortex mixed for a few seconds and then centrifuged for approx. 1 min. A 50-microliter sample of the clear supernatant was injected into the chromatograph. A mu Bondapak C18 reversed-phase column was used with a mobile phase acetonitrile--0.05% phosphoric acid (45:55) at a flow-rate of 1.5 ml/min. The column effluent was monitored by a variable-wavelength UV detector set at 200 nm. Tolbutamide and its metabolite had retention times of 5.75 and 3.25 min, respectively. The procedure yuelds reproducible results with sensitivity adequate for routine clinical monitoring of plasma levels or for single-dose pharmacokinetic studies. A number of commonly used drugs do not interfere with the method. A single plasma sample can be analyzed in approx. 9 or 10 min.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 757962     DOI: 10.1016/s0378-4347(00)81296-7

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.

Authors:  J O Miners; T Foenander; S Wanwimolruk; A S Gallus; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.

Authors:  L Balant
Journal:  Clin Pharmacokinet       Date:  1981 May-Jun       Impact factor: 6.447

3.  The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes.

Authors:  R E Ferner; M L Antsiferov; A W Kelman; K G Alberti; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.

Authors:  L M Tremaine; K D Wilner; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

5.  Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers.

Authors:  K D Wilner; M J Gardner
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

6.  Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.

Authors:  D J Back; F Sutcliffe; J F Tjia
Journal:  Br J Pharmacol       Date:  1984-03       Impact factor: 8.739

7.  Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.

Authors:  L M Wing; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

8.  Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.

Authors:  J O Miners; L M Wing; K J Lillywhite; K J Smith
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.